title: Prognostic factors in a prospective series of papillary renal cell carcinoma.
abstract: OBJECTIVE
  To prospectively assess the clinical outcome of a series of papillary renal cell carcinomas (PRCCs) to identify possible prognostic clinical variables and tumour markers, as previous retrospective series of PRCC do not provide unanimous results on the prognostic utility of clinicopathological variables.
  
  
  METHODS
  Forty-six patients with PRCC (median follow-up 40 months) diagnosed in one institution from 1989 to 2002 were prospectively followed until May 2006. The pathology was reviewed, the PRCC subtyped (type 1 and 2) and immunohistochemistry assessed for MIB-1, vascular endothelial growth factor (VEGF), CD31 and c-met oncogenic protein, by a referee pathologist. Prognostic values were estimated by fitting a Cox model.
  
  
  RESULTS
  The 5-year survival rate was 49.5%; type 2 histology was predominant and was almost significant in the univariate analysis. Stage and MIB-1 were significant prognostic factors only in the univariate model, while the Cox model identified only the Fuhrman grade as an independent predictor of survival (hazard ratio 3.054; P = 0.007). MET expression, CD31 and VEGF had no prognostic utility.
  
  
  CONCLUSIONS
  These patients with PRCC followed prospectively fared worse than in previously reported series. The Fuhrman grade was the sole independent predictor of survival.
authors.affiliation: Dipartimento di Discipline Medico Chirurgiche, Clinica Urologica, University of Torino, Torino, Italy. paolo.gontero@unito.it
authors.forename: Paolo
authors.initials: P
authors.lastname: Gontero
authors.forename: Giovanni
authors.initials: G
authors.lastname: Ceratti
authors.forename: Sandro
authors.initials: S
authors.lastname: Guglielmetti
authors.forename: Antonella
authors.initials: A
authors.lastname: Andorno
authors.forename: Carlo
authors.initials: C
authors.lastname: Terrone
authors.forename: Daniele
authors.initials: D
authors.lastname: Bonvini
authors.forename: Fabrizio
authors.initials: F
authors.lastname: Faggiano
authors.forename: Alessandro
authors.initials: A
authors.lastname: Tizzani
authors.forename: Bruno
authors.initials: B
authors.lastname: Frea
authors.forename: Guido
authors.initials: G
authors.lastname: Valente
mesh_terms: D000368:Aged; D000974:Antibodies, Antinuclear / Q000378:metabolism; D000911:Antibodies, Monoclonal / Q000378:metabolism; D014408:Biomarkers, Tumor / Q000378:metabolism*; D002292:Carcinoma, Renal Cell / Q000401:mortality / Q000473:pathology* / Q000601:surgery; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D019394:Ki-67 Antigen / Q000378:metabolism; D007680:Kidney Neoplasms / Q000401:mortality / Q000473:pathology* / Q000601:surgery; D008297:Male; D008875:Middle Aged; D009392:Nephrectomy / Q000379:methods*; D019408:Platelet Endothelial Cell Adhesion Molecule-1 / Q000378:metabolism; D011379:Prognosis; D011446:Prospective Studies; D019859:Proto-Oncogene Proteins c-met / Q000378:metabolism; D015996:Survival Rate; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism
chemical_list: D000974:Antibodies, Antinuclear; D000911:Antibodies, Monoclonal; D014408:Biomarkers, Tumor; D019394:Ki-67 Antigen; C440408:MIB-1 antibody; D019408:Platelet Endothelial Cell Adhesion Molecule-1; D042461:Vascular Endothelial Growth Factor A; D019859:Proto-Oncogene Proteins c-met